Cargando…
Anti-angiogenesis gene therapy for hepatocellular carcinoma via systemic injection of mesenchymal stem cells engineered to secrete soluble Flt-1
Anti-angiogenesis gene therapy has attracted interest as a potential treatment for hepatocellular carcinoma (HCC). Studies have indicated that soluble fms-like tyrosine kinase-1 (sFlt-1) may suppress angiogenesis by sequestering free vascular endothelial growth factor (VEGF) or by forming inactive h...
Autores principales: | Li, Guanglin, Miao, Fei, Zhu, Jinhai, Chen, Yanling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865760/ https://www.ncbi.nlm.nih.gov/pubmed/28849176 http://dx.doi.org/10.3892/mmr.2017.7310 |
Ejemplares similares
-
Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis
por: Ahmad, Shakil, et al.
Publicado: (2011) -
Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1
por: Shen, Fanxia, et al.
Publicado: (2015) -
Soluble Flt-1 in AMI Patients Serum Inhibits Angiogenesis of Endothelial Progenitor Cells by Suppressing Akt and Erk’s Activity
por: Zhang, Lijie, et al.
Publicado: (2022) -
Secretion of interleukin-6 by bone marrow mesenchymal stem cells
promotes metastasis in hepatocellular carcinoma
por: Mi, Fei, et al.
Publicado: (2017) -
Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model
por: Hu, M, et al.
Publicado: (2008)